RSS

endocrine therapy

The US FDA has approved Verzenio (abemaciclib), from Eli Lilly and Company, for the treatment of adult patients who have HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. more

News